Fatemeh Sheikhbahaei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Fatemeh Sheikhbahaei has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Fahimeh Pourjafari
Anatomical Sciences Department, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran
2 shared publications - Seyed Noureddin Nematollahi-Mahani
Department of Anatomical Sciences, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran
2 shared publications - Tahereh Haghpanah
Anatomical Sciences Department, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran
2 shared publications - Ali Shamsara
Department of Anatomy, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran
1 shared publication - Amir Asadi
Herbal and Traditional Medicines Research Center, Institute of pharmaceutical Sciences, Kerman University of Medical Sciences, Kerman, Iran
1 shared publication - Ashkan Delavari
Department of Hematology and Biochemistry, Al Basma Specialized Hospital, Oman
1 shared publication
Latest Publications
- 18 November 2026
- Published by Springer Nature in Journal of Molecular Histology
- Vol. 58 (1)
Neuroprotective effects of the petroleum ether fraction of Teucrium polium in free and lipid nanoparticle formulations on cognitive deficits and oxidative stress in an ICV-STZ-induced Alzheimer’s-like rat model
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, oxidative stress, and neuronal loss. Current pharmacological treatments provide only partial symptomatic relief. This study investigated the neuroprotective effects of the petroleum ether fraction of Teucrium polium (T. polium), administered in both free and lipid nanoparticle formulations (T. polium-LNP), in a rat model of AD-like pathology induced by intracerebroventricular streptozotocin (ICV-STZ). Adult male Wistar rats were divided into five groups: Control, ICV-STZ, ICV-STZ + Memantine, ICV-STZ + T. polium, and ICV-STZ + T. polium-LNP. Cognitive function was assessed using the Morris water maze (MWM) and novel object recognition (NOR) tests. Serum oxidative stress markers-including malondialdehyde (MDA), total antioxidant capacity (TAC), and superoxide dismutase (SOD) activity-were measured. Hippocampal CA1 histopathology and hippocampal mRNA expression of Bax, Bcl-2, and p53 were also evaluated. The ICV-STZ-induced AD-like model was associated with memory impairment, increased serum MDA levels, reduced TAC levels and SOD activity, and hippocampal CA1 neuronal damage, accompanied by increased Bax and p53 expression and decreased Bcl-2 expression. Treatment with T. polium and T. polium-LNP improved cognitive performance, particularly spatial memory in the MWM, and attenuated several pathological changes. Both treatments reduced serum MDA levels and decreased CA1 neuronal degeneration. In this experimental AD-like rat model, both formulations of T. polium were associated with improvements in cognitive performance, serum oxidative status markers, and hippocampal tissue changes. Although T. polium-LNP showed numerically greater effects on several outcomes, direct comparisons between the free T. polium extract and T. polium-LNP were statistically significant only for CA1 neuronal damage. Further mechanistic and long-term studies are needed to clarify the potential relevance of these findings to AD-related neuroprotection.
- 18 November 2026
- Published by Springer Nature in Journal of Molecular Histology
- Vol. 58 (1)
Neuroprotective effects of the petroleum ether fraction of Teucrium polium in free and lipid nanoparticle formulations on cognitive deficits and oxidative stress in an ICV-STZ-induced Alzheimer’s-like rat model
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, oxidative stress, and neuronal loss. Current pharmacological treatments provide only partial symptomatic relief. This study investigated the neuroprotective effects of the petroleum ether fraction of Teucrium polium (T. polium), administered in both free and lipid nanoparticle formulations (T. polium-LNP), in a rat model of AD-like pathology induced by intracerebroventricular streptozotocin (ICV-STZ). Adult male Wistar rats were divided into five groups: Control, ICV-STZ, ICV-STZ + Memantine, ICV-STZ + T. polium, and ICV-STZ + T. polium-LNP. Cognitive function was assessed using the Morris water maze (MWM) and novel object recognition (NOR) tests. Serum oxidative stress markers-including malondialdehyde (MDA), total antioxidant capacity (TAC), and superoxide dismutase (SOD) activity-were measured. Hippocampal CA1 histopathology and hippocampal mRNA expression of Bax, Bcl-2, and p53 were also evaluated. The ICV-STZ-induced AD-like model was associated with memory impairment, increased serum MDA levels, reduced TAC levels and SOD activity, and hippocampal CA1 neuronal damage, accompanied by increased Bax and p53 expression and decreased Bcl-2 expression. Treatment with T. polium and T. polium-LNP improved cognitive performance, particularly spatial memory in the MWM, and attenuated several pathological changes. Both treatments reduced serum MDA levels and decreased CA1 neuronal degeneration. In this experimental AD-like rat model, both formulations of T. polium were associated with improvements in cognitive performance, serum oxidative status markers, and hippocampal tissue changes. Although T. polium-LNP showed numerically greater effects on several outcomes, direct comparisons between the free T. polium extract and T. polium-LNP were statistically significant only for CA1 neuronal damage. Further mechanistic and long-term studies are needed to clarify the potential relevance of these findings to AD-related neuroprotection.
- 3 November 2026
- Published by IGI Global Scientific Publishing
- p. 245-282
Recently Developed Synthetic Inhibitors for Major Depressive Disorder Treatment
Major depressive disorder (MDD) pathophysiology extends beyond traditional monoaminergic mechanisms to include neuroinflammation, oxidative stress, mitochondrial dysfunction, and impaired neuroplasticity. This chapter comprehensively reviews emerging synthetic inhibitors targeting these non-monoaminergic pathways. Key therapeutic classes include NLRP3 inflammasome inhibitors, TNF-α antagonists, soluble epoxide hydrolase (sEH) inhibitors, NADPH oxidase (NOX) inhibitors, PARP inhibitors, and modulators of glycogen synthase kinase-3 (GSK-3) and Rho-associated protein kinase (ROCK). Preclinical evidence demonstrates robust efficacy in reversing depression-like behaviors and restoring synaptic plasticity. While several candidates show favorable pharmacokinetic profiles, clinical translation remains limited, necessitating optimized CNS penetration, biomarker-driven trials, and personalized treatment approaches for treatment-resistant depression.
- 3 November 2026
- Published by IGI Global Scientific Publishing
- p. 245-282
Recently Developed Synthetic Inhibitors for Major Depressive Disorder Treatment
Major depressive disorder (MDD) pathophysiology extends beyond traditional monoaminergic mechanisms to include neuroinflammation, oxidative stress, mitochondrial dysfunction, and impaired neuroplasticity. This chapter comprehensively reviews emerging synthetic inhibitors targeting these non-monoaminergic pathways. Key therapeutic classes include NLRP3 inflammasome inhibitors, TNF-α antagonists, soluble epoxide hydrolase (sEH) inhibitors, NADPH oxidase (NOX) inhibitors, PARP inhibitors, and modulators of glycogen synthase kinase-3 (GSK-3) and Rho-associated protein kinase (ROCK). Preclinical evidence demonstrates robust efficacy in reversing depression-like behaviors and restoring synaptic plasticity. While several candidates show favorable pharmacokinetic profiles, clinical translation remains limited, necessitating optimized CNS penetration, biomarker-driven trials, and personalized treatment approaches for treatment-resistant depression.
- 5 October 2026
- Published by Springer Nature in Journal of Molecular Histology
- Vol. 57 (5) , 329
Foeniculum vulgare and metformin combination improve ovarian function in a rat model of polycystic ovary syndrome: targeting AMH imbalances, folliculogenesis disruption, fibrosis, and abnormal vascular density
- 5 October 2026
- Published by Springer Nature in Journal of Molecular Histology
- Vol. 57 (5) , 329
Foeniculum vulgare and metformin combination improve ovarian function in a rat model of polycystic ovary syndrome: targeting AMH imbalances, folliculogenesis disruption, fibrosis, and abnormal vascular density
- 19 May 2026
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 41 (1) , 99
From tumor reduction to behavioral improvement and cytokine balance: Therapeutic role of petroleum ether extract of Teucrium polium in a rat model of C6-induced glioblastoma
This study aimed to investigate the therapeutic effects of the petroleum ether extract of Teucrium polium (T. polium) on cognitive behaviors, oxidative stress, interleukin-1 beta (IL-1β) and interleukin10 (IL-10) cytokines, tumor volume, and survival rate on C6-induced glioblastoma multiforme (GBM) in rats. The rats were randomly divided into seven groups (n = 10): sham, tumor, vehicle, Temozolomide (TMZ), and T. polium at doses of 1, 2, 4 mg/kg. Behavioral assessments were performed using the open field test (OFT), elevated plus maze (EPM), rotarod test (RT), and passive avoidance test (PAT) to examine anxiety-like behavior, motor function, and memory. Positron Emission Tomography (PET( imaging was performed on day 25. Histopathological changes, and Ki-67 were assessed using Hematoxylin and Eosin (H&E) and Immunohistochemistry (IHC), and the tumor area was measured. Malondialdehyde (MDA), total antioxidant capacity (TAC), and IL-1β and IL-10 cytokines in brain tissue were evaluated. Survival rate was also assessed for three months. T. polium, especially at a dose of 2 mg/kg could inhibit GBM proliferation and reduce tumor area and Fluorodeoxyglucose )FDG( uptake. T. polium, particularly at the higher doses, improved anxiety-like behaviour and motor dysfunction. IL-1β and IL-10 reduced in the treatment groups. It should be mentioned that T. polium could not improve memory, survival rate, and oxidant status. Considering the anti-anxiety and anti-tumor properties of T. polium and its neuroprotective effects in rats with GBM, it may be regarded as a complementary therapeutic agent to TMZ in the treatment of GBM. Further studies are needed to clarify the underlying mechanisms and their clinical significance.
- 19 May 2026
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 41 (1) , 99
From tumor reduction to behavioral improvement and cytokine balance: Therapeutic role of petroleum ether extract of Teucrium polium in a rat model of C6-induced glioblastoma
This study aimed to investigate the therapeutic effects of the petroleum ether extract of Teucrium polium (T. polium) on cognitive behaviors, oxidative stress, interleukin-1 beta (IL-1β) and interleukin10 (IL-10) cytokines, tumor volume, and survival rate on C6-induced glioblastoma multiforme (GBM) in rats. The rats were randomly divided into seven groups (n = 10): sham, tumor, vehicle, Temozolomide (TMZ), and T. polium at doses of 1, 2, 4 mg/kg. Behavioral assessments were performed using the open field test (OFT), elevated plus maze (EPM), rotarod test (RT), and passive avoidance test (PAT) to examine anxiety-like behavior, motor function, and memory. Positron Emission Tomography (PET( imaging was performed on day 25. Histopathological changes, and Ki-67 were assessed using Hematoxylin and Eosin (H&E) and Immunohistochemistry (IHC), and the tumor area was measured. Malondialdehyde (MDA), total antioxidant capacity (TAC), and IL-1β and IL-10 cytokines in brain tissue were evaluated. Survival rate was also assessed for three months. T. polium, especially at a dose of 2 mg/kg could inhibit GBM proliferation and reduce tumor area and Fluorodeoxyglucose )FDG( uptake. T. polium, particularly at the higher doses, improved anxiety-like behaviour and motor dysfunction. IL-1β and IL-10 reduced in the treatment groups. It should be mentioned that T. polium could not improve memory, survival rate, and oxidant status. Considering the anti-anxiety and anti-tumor properties of T. polium and its neuroprotective effects in rats with GBM, it may be regarded as a complementary therapeutic agent to TMZ in the treatment of GBM. Further studies are needed to clarify the underlying mechanisms and their clinical significance.